Medtronic's most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $96.00 short put and a strike $91.00 long put offers a potential 27.23% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $96.00 by expiration. The full premium credit of $1.07 would be kept by the premium seller. The risk of $3.93 would be incurred if the stock dropped below the $91.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.
The RSI indicator is at 78.12 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
Medtronic EVP & MITG President Bob White to Speak at Wells Fargo Securities Healthcare Conference
Tue, 28 Aug 2018 15:01:01 +0000
August 28, 2018 – Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the 13th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 6, 2018, in Boston. Bob White, executive vice president and president of the Minimally Invasive Therapies Group (MITG) of Medtronic, will answer questions about the company beginning at 10:55 a.m. EDT (9:55 a.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world.
Study Shows Improved Quality of Life and Reduced Symptoms In Patients Treated with Medtronic Cryoballoon
Tue, 28 Aug 2018 13:02:01 +0000
August 28, 2018 – Medtronic plc (MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced symptoms from abnormal heart rhythms, and low incidence of reinterventions and repeat ablation procedures. The study evaluated patients with symptomatic persistent atrial fibrillation (AF) treated with the Medtronic Arctic Front Advance(TM) Cryoballoon, and the results were presented at the 2018 European Society of Cardiology (ESC) Congress in Munich. The Arctic Front Advance Cryoablation System is not approved for treating persistent AF in the United States.
Medtronic CEO Omar Ishrak's compensation up 12 percent
Mon, 27 Aug 2018 19:12:06 +0000
The majority of Ishrak's bump came from a roughly $2 million increase in his non-equity incentive plan.
How Wall Street Analysts View Medtronic after Fiscal Q1 2019
Mon, 27 Aug 2018 13:01:33 +0000
In August, Medtronic launched the IN.PACT Admiral Drug-Coated Balloon in Japan. In 2017, IN.PACT received approval from the Japanese Ministry of Health, Labor and Welfare (or MHLW) for the treatment of individuals with peripheral artery disease in the upper leg (the thigh and behind the knee).
An Update on MDT’s Restorative Therapies after Fiscal Q1 2019
Mon, 27 Aug 2018 11:31:47 +0000
Medtronic’s (MDT) Restorative Therapies Group reported revenue of $1.9 billion in the fiscal first quarter of 2019 compared to $1.8 billion in the fiscal first quarter of 2018, reflecting ~8% YoY (year-over-year) growth. In the quarter, in US, non-US developed, and emerging markets, Medtronic’s Restorative Therapies Group reported revenues of $1.3 billion, $428.0 million, and $227.0 million, respectively, compared to $1.2 billion, $394.0 million, and $194.0 million, respectively, in the fiscal first quarter of 2018, reflecting YoY rises of ~6%, ~9%, and ~17%, respectively. In the quarter, Medtronic’s Spine segment generated revenue of $652.0 million compared to $649.0 million in the fiscal first quarter of 2018. In the US market, the segment reported revenue of $444.0 million, reflecting a ~2% YoY fall.
Also on Market Tamer…
Follow Us on Facebook